MS-Selfie Q&A 9

A natalizumab biosimilar, BTK inhibitors and MS online resources.

Questions

Q1: I was told by my MS nurse specialist that I would almost certainly have to switch to a new version of natalizumab (Tysabri) in the New Year. Is that correct? If yes, what should I expect from a new form of natalizumab?

Q2: BTK inhibitors were big news at ECTRIMS 2023 in Milan. If they do make it into the clinic, how do you see them being used in MS, i.e. first line, in early or advanced MS or as an add-on therapy?

Q3: I receive various email updates from you that are all great, but I need clarification on the difference between them. Initially, there were MS-Selfie emails sent out. At one stage, some emails were marked microsite, some substack and some for paid-up subscribers. Please clarify the difference for me. I am happy to subscribe to your stirling efforts, but I need help finding information on how to do so. Help.

NOTE: General substack newsletters and microsite are free; it is only Q&A sessions that are restricted to paying subscribers. I can't run and maintain the MS-Selfie microsite, hence the need to pay people to help do the work for me. If people want to ask medical questions unrelated to the Newsletters or Podcasts, they either need to become paying subscribers or email (ms-selfie@giovannoni.net) to request a complimentary subscription.

Answers